to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: HLX10|DRUG: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|DRUG: Placebo
Sponsor: Shanghai Henlius Biotech